Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma

2 Mar 2022

Abstract excerpt

The excellent article by Frappaz et al., entitled “MEVITEM - A Phase I/II of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation” (Neuro Oncol. 2021; 23(11):1949-1960. doi:10.1093/neuonc/noab087) reports results from the MEVITEM phase I/II trial, which explored the toxicity and efficacy of adding vismodegib to temozolomide in adult...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Glioma Diagnosis and Treatment
Share to Hedgehog Signaling Pathway Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35552442
DOI: 10.1093/neuonc/noac061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastomaPMID 35552442Read ↗

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032Semantic proximity Read ↗

Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult MedulloblastomaSemantic proximity Read ↗

The SHH/GLI signaling pathway: a therapeutic target for medulloblastomaSemantic proximity Read ↗

Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegibSemantic proximity Read ↗

Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysisSemantic proximity Read ↗

Hedgehog Fights Back: Mechanisms of Acquired Resistance against Smoothened AntagonistsSemantic proximity Read ↗

Sonic hedgehog signalling pathway in CNS tumours: its role and therapeutic implicationsSemantic proximity Read ↗

Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.Semantic proximity Read ↗

Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapySemantic proximity Read ↗

PTEN Loss Mitigates the Response of Medulloblastoma to Hedgehog Pathway InhibitionSemantic proximity Read ↗

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.Semantic proximity Read ↗

Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.